RT Journal Article
SR Electronic
T1 Are we there yet? An adaptive SIR model for continuous estimation of COVID-19 infection rate and reproduction number in the United States
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.13.20193896
DO 10.1101/2020.09.13.20193896
A1 Shapiro, Mark B
A1 Karim, Fazle
A1 Muscioni, Guido
A1 Augustine, Abel Saju
YR 2020
UL http://medrxiv.org/content/early/2020/11/02/2020.09.13.20193896.abstract
AB Background The dynamics of the COVID-19 epidemic vary due to local population density and policy measures. When making decisions, policy makers consider an estimate of the effective reproduction number ℛt which is the expected number of secondary infections by a single infected individual.Objective We propose a simple method for estimating the time-varying infection rate and reproduction number ℛt.Methods We use a sliding window approach applied to a Susceptible-Infectious-Removed model. The infection rate is estimated using the reported cases for a seven-day window to obtain continuous estimation of ℛt. The proposed adaptive SIR (aSIR) model was applied to data at the state and county levels.Results The aSIR model showed an excellent fit for the number of reported COVID-19 positive cases, a one-day forecast MAPE was less than 2.6% across all states. However, a seven-day forecast MAPE reached 16.2% and strongly overestimated the number of cases when the reproduction number was high and changing fast. The maximal ℛt showed a wide range of 2.0 to 4.5 across all states, with the highest values for New York (4.4) and Michigan (4.5). We demonstrate that the aSIR model can quickly adapt to an increase in the number of tests and associated increase in the reported cases of infections. Our results also suggest that intensive testing may be one of the effective methods of reducing ℛt.Conclusion The aSIR model provides a simple and accurate computational tool to obtain continuous estimation of the reproduction number and evaluate the efficacy of mitigation measures.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research was done on publicly available data, no IRB requiredAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data on daily and cumulative confirmed cases between February 29, 2020 and September 2, 2020 were obtained from John Hopkins University. The dates of interventions by states were obtained from Wikipedia. State level data were extracted directly from the Centers for Disease Control website. The code is available on github https://github.com/fazlekarim-anthem/aSIR